USPTO Seeks Feedback on Patent Attorney Roster Update Procedures
Published Date: 3/18/2026
Notice
Summary
The USPTO is asking for public feedback on updating how they collect info about patent attorneys and agents who can practice before them. This affects patent pros who want to stay on the official roster and keep practicing. Comments are open until May 18, 2026, with no new fees, just a smoother info update process.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Application and Filing Fees Required
Applicants must pay listed non-refundable fees when filing: a $118 application fee for registration (3,293 responses), a $124 fee for extension requests (764 responses), and other fees (e.g., $226 on-registration fee for 1,094 responses). The USPTO estimates total annual non-hour filing fees of $798,086 associated with these responses.
Overall Estimated Annual Burden and Costs
The USPTO estimates 11,085 annual respondents and 11,085 annual responses (overall figures listed), with a total estimated annual respondent burden of 2,767 hours and an estimated total annual respondent hourly cost burden of $1,236,849. The Agency also estimates total annual non-hour respondent costs of $798,130 (filing fees and postage).
New Undertaking Form Added
The USPTO is adding Item 6 (Undertaking Under 37 CFR 11.10(b)) as form PTO-275 to this information collection. The Agency estimates 61 annual responses for this item, each taking about 0.50 hours (30 minutes), producing an estimated annual respondent cost burden of $13,857.
Certain Forms Removed as Exempt
The USPTO removed several items from this information collection because OMB declared them exempt under 5 CFR 1320.3(h)(1), 1320.3(h)(2), and 1320.3(h)(7). Removed items include: Registration Examination to Become a Registered Practitioner (Reasonable Accommodation--PTO 158RA), Change of Registration from Agent to Attorney (PTO 158), and Written Requests (Certificate of Good Standing, Disciplinary History).
No Notarization Required for Oath
The USPTO no longer requires the Oath or Affirmation (PTO-1209) to be notarized when submitted. This eliminates notary costs previously incurred by attorneys or agents for that submission.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2026-05218, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. This is a routine check to make sure the questions they ask aren’t too much work and actually help them do their job better. If you have ideas or concerns, you’ve got until April 17, 2026, to speak up—no money changes, just your chance to help shape the process!
Next: 2026-05222, Notice of Formal Determination on Records Release
The Civil Rights Cold Case Records Review Board decided to release most pages from two important civil rights cold case files, making 1,623 pages available to the public. Some sensitive information will stay sealed for now, but the Board might revisit that later. These decisions follow a law that requires quick public updates and don’t involve any new costs or deadlines for the public.